title: Successful desensitization to brentuximab vedotin after anaphylaxis.
authors.affiliation: Department of Allergy/Immunology, Boston Children's Hospital, Boston, MA. Electronic address: amy.oconnell@childrens.harvard.edu.
authors.forename: Amy E
authors.initials: AE
authors.lastname: O'Connell
authors.affiliation: Department of Pharmacy, Boston Children's Hospital, Boston, MA.
authors.forename: Joyce P
authors.initials: JP
authors.lastname: Lee
authors.affiliation: Department of Allergy/Immunology, Boston Children's Hospital, Boston, MA.
authors.forename: Christina
authors.initials: C
authors.lastname: Yee
authors.affiliation: Dana-Farber/Boston Children's Center for Cancer and Blood Disorders, Boston, MA.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Kesselheim
authors.affiliation: Department of Allergy/Immunology, Boston Children's Hospital, Boston, MA.
authors.forename: Anahita
authors.initials: A
authors.lastname: Dioun
mesh_terms: D000707:Anaphylaxis / Q000517:prevention & control*; D000079963:Brentuximab Vedotin; D003888:Desensitization, Immunologic / Q000379:methods*; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D017728:Lymphoma, Large-Cell, Anaplastic / Q000628:therapy*; D008297:Male; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D018796:Immunoconjugates; D000079963:Brentuximab Vedotin
keywords: Anaphylaxis; Anaplastic large cell lymphoma; Brentuximab vedotin; Desensitization; Drug allergy